ACCURAY INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $ARAY in the last 30 days.
See all $ARAY insider activity →Accuray (ARAY) stockholders approved financing-related proposals, enabling transactions with TCW Asset Management, including debt exchange, equity investment, and a reverse stock split. The company also appointed Richard A. Meier to its board. The moves aim to strengthen Accuray's financial position and support long-term value creation.
Accuray (ARAY) and Samsung NeuroLogica have partnered to advance volumetric imaging for the CyberKnife System. The collaboration aims to enhance treatment efficiency and decision-making, addressing customer priorities. Key clinicians highlighted the potential benefits for various cancer treatments. The partnership is part of Accuray's strategy to accelerate innovation through targeted collaborations.
Accuray (ARAY) has agreed to an $8 million deal with RaySearch to integrate their technologies, accelerating online adaptive radiation therapy. The collaboration focuses on Accuray's Radixact and CyberKnife platforms, aiming to enhance personalized treatments. Accuray's transformation plan has already exceeded cost and margin improvement targets by $20 million for fiscal 2026. Risks include slow adoption and third-party dependency on RaySearch. Institutional investment in ARAY has increased, wit
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ARAY (ACCURAY INC). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent ARAY coverage spans earnings, technology and financial news.
Financing clears liquidity constraints; reverse split may cause short-term volatility.
The partnership could enhance Accuray's product offering and may be viewed positively by investors, but no immediate revenue or product launch is confirmed.
The deal could boost Accuray's adaptive therapy offerings but adoption risk and reliance on RaySearch may limit near‑term revenue impact.
Potential modest revenue boost and expanded market for Accuray's adaptive therapy platforms.
Large insider stake may signal contrarian belief in turnaround, but financial distress remains severe.
AlphAI scores every news story that mentions ARAY with an AI model for sentiment and relevance, and aggregates insider trades from ACCURAY INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Accuray (ARAY) stockholders approved financing-related proposals, enabling transactions with TCW Asset Management, including debt exchange, equity investment, and a reverse stock split. The company also appointed Richard A. Meier to its board. The moves aim to strengthen Accuray's financial position and support long-term value creation.
2 min readAccuray (ARAY) and Samsung NeuroLogica have partnered to advance volumetric imaging for the CyberKnife System. The collaboration aims to enhance treatment efficiency and decision-making, addressing customer priorities. Key clinicians highlighted the potential benefits for various cancer treatments. The partnership is part of Accuray's strategy to accelerate innovation through targeted collaborations.
2 min readAccuray (ARAY) has agreed to an $8 million deal with RaySearch to integrate their technologies, accelerating online adaptive radiation therapy. The collaboration focuses on Accuray's Radixact and CyberKnife platforms, aiming to enhance personalized treatments. Accuray's transformation plan has already exceeded cost and margin improvement targets by $20 million for fiscal 2026. Risks include slow adoption and third-party dependency on RaySearch. Institutional investment in ARAY has increased, wit
3 min readRaySearch (STO: RAY B) and Accuray (NASDAQ: ARAY) agreed to expand their collaboration to accelerate online adaptive radiation therapy. Accuray will purchase RayStation licenses worth $8M, recognized as revenue in 2026. The partnership combines Accuray's platforms with RaySearch's software for personalized treatments.
2 min readTCW Group Inc increased its stake in Accuray Inc (ARAY) by 8.59 million shares at $0.2309 per share, now owning 18.70% of ARAY. Accuray, a radiation oncology company, has a market cap of $31.3M and faces severe financial distress, with a Piotroski F-Score of 1 and an Altman Z-Score of -0.69. TCW Group's total equity holdings are valued at $14.87B, with a portfolio preference for technology and industrials.
2 min readAccuray Inc. amended a major shareholder report, detailing a $55M issuance of Series A Convertible Preferred Stock to investors, including affiliates of the reporting person. The deal involves $15M in cash and $40M in debt conversion, with warrants issued as incentives. The transaction is subject to closing conditions and stockholder approval. If not approved, a $15M fee is payable. The Series A Preferred Stock is convertible into common stock at $0.50 per share. TCW Asset Management gains board
2 min readAccuray (ARAY) reported a 21% revenue decline to $100.9M in Q4 2026, with China's market contributing to a 42% drop in product revenue. The company secured $60M in financing from TCW Asset Management, improving its balance sheet. Service revenue grew 6%, and cost savings exceeded targets. However, Accuray did not provide 2027 guidance due to trade policy uncertainties.
3 min readAccuray (ARAY) reported Q4 2026 revenue of $100.9M, down 21% YoY, with product revenue declining 42% due to geopolitical tensions. Service revenue grew 6% to $60.1M. Full-year revenue was $401.9M, down 12%. The company realized $20M in cost savings and expects $15M more in FY27. Adjusted EBITDA was $12.9M, up from $9.4M YoY. Management cited trade policy uncertainty and regional volatility as risks.
3 min readAccuray Incorporated reported Q4 2026 earnings, noting a $58M revenue decline due to China's geopolitical tensions. The company is shifting to a partner-centric model and saw 6% service revenue growth. Management highlighted clinical data validating their technology and $20M in cost improvements. No formal guidance was given for 2027 due to uncertainty. A debt-to-equity conversion with TCW and a reverse stock split plan were announced.
3 min readAccuray Inc (ARAY) reported a 12% year-over-year revenue decline to $402M for fiscal 2026, with product revenue down 27% due to China sales drop. Gross margin fell to 27.7% from 32.1%, and operating loss was $26.4M. Management cited geopolitical tensions and tariff uncertainty. The company secured $55M in funding from TCW Asset Management, converting debt and receiving cash investment. Service revenue grew 4% year-over-year, and the company aims to improve cost structure and market reach in fisc
2 min read
